Shanghai Henlius Biotech (HKG:2696) recently dosed the first patient in a phase 2 clinical study of HLX22 in combination with trastuzumab deruxtecan, an April 17 Hong Kong bourse filing said.
The drug is being tested in the trial for the treatment of patients with locally advanced or metastatic breast cancer in mainland China, excluding the Hong Kong, Macau, and Taiwan regions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.